[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

WO2010036813A8 - Composes et methodes de prevention ou de traitement des affections neurodegeneratives associees a une accumulation de peptides abeta - Google Patents

Composes et methodes de prevention ou de traitement des affections neurodegeneratives associees a une accumulation de peptides abeta Download PDF

Info

Publication number
WO2010036813A8
WO2010036813A8 PCT/US2009/058246 US2009058246W WO2010036813A8 WO 2010036813 A8 WO2010036813 A8 WO 2010036813A8 US 2009058246 W US2009058246 W US 2009058246W WO 2010036813 A8 WO2010036813 A8 WO 2010036813A8
Authority
WO
WIPO (PCT)
Prior art keywords
preventing
neurodegenerative conditions
animal
disease
conditions associated
Prior art date
Application number
PCT/US2009/058246
Other languages
English (en)
Other versions
WO2010036813A1 (fr
Inventor
Valentina Echeverria Moran
Gary W Arendash
Original Assignee
University Of South Florida
United States Department Of Veterans Affairs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University Of South Florida, United States Department Of Veterans Affairs filed Critical University Of South Florida
Priority to US13/120,633 priority Critical patent/US20110243957A1/en
Publication of WO2010036813A1 publication Critical patent/WO2010036813A1/fr
Publication of WO2010036813A8 publication Critical patent/WO2010036813A8/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne des méthodes de prévention et/ou de traitement des affections neurodégénératives associées à une accumulation de peptides Abeta dans le tissu nerveux d'un humain ou d'un animal. L'invention concerne également des méthodes de prévention ou de traitement d'une neuropathologie de type maladie d'Alzheimer chez une personne ou un animal présentant une trisomie 21 (syndrome de Down). Dans un mode de réalisation, une méthode selon l'invention consiste à administrer à une personne ou un animal nécessitant un tel traitement une quantité thérapeutiquement efficace d'un composé qui inhibe la fonction ou l'activité d'une protéine Raf. Dans un mode de réalisation spécifique, l'inhibiteur de Raf est du Sorafénib (NEXAVAR). Les affections neurodégénératives ciblées par la présente invention comprennent, entre autres, la maladie d'Alzheimer et la maladie de Parkinson. L'invention concerne également des méthodes destinées à prévenir ou inhiber la mort des cellules neuronales et/ou améliorer la viabilité cellulaire.
PCT/US2009/058246 2008-09-24 2009-09-24 Composes et methodes de prevention ou de traitement des affections neurodegeneratives associees a une accumulation de peptides abeta WO2010036813A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/120,633 US20110243957A1 (en) 2008-09-24 2009-09-24 Materials and methods for preventing or treating neurodegenerative conditions associated with abeta peptide accumulation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9976108P 2008-09-24 2008-09-24
US61/099,761 2008-09-24

Publications (2)

Publication Number Publication Date
WO2010036813A1 WO2010036813A1 (fr) 2010-04-01
WO2010036813A8 true WO2010036813A8 (fr) 2010-05-27

Family

ID=42060089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/058246 WO2010036813A1 (fr) 2008-09-24 2009-09-24 Composes et methodes de prevention ou de traitement des affections neurodegeneratives associees a une accumulation de peptides abeta

Country Status (2)

Country Link
US (1) US20110243957A1 (fr)
WO (1) WO2010036813A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2901402T3 (es) 2013-02-22 2022-03-22 Univ Leland Stanford Junior Uso médico relacionado con la extensión telomérica
US20140357676A1 (en) * 2013-05-28 2014-12-04 National Defense Medical Center Pharmaceutical compositions and methods for treating cancer and biomarkers for drug screening
EP3222276B1 (fr) * 2014-11-19 2021-04-07 National Defense Medical Center Composition pharmaceutique pour le traitement du cancer et biomarqueur pour le criblage de médicament
KR101786859B1 (ko) * 2015-04-30 2017-10-17 서울대학교산학협력단 혈장 내 아밀로이드베타의 농도를 통해 알츠하이머병을 임상학적 및 병리학적으로 모니터링하는 방법
US20240245806A1 (en) * 2021-05-27 2024-07-25 Brown University Treatment of neurodegenerative disease using csa- and indy-type compounds
CN113373098B (zh) * 2021-07-28 2022-07-01 西安医学院 一株可用于治疗阿尔茨海默病的寡养单胞菌h2株及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2475703C (fr) * 2002-02-11 2016-12-20 Bayer Pharmaceuticals Corporation Urees aryliques a activite inhibitrice d'angiogenese
US20050250837A1 (en) * 2002-10-18 2005-11-10 D Mello Santosh R Use of C-Raf inhibitors for the treatment of neurodegenerative diseases
US20050147593A1 (en) * 2003-05-22 2005-07-07 Medimmune, Inc. EphA2, EphA4 and LMW-PTP and methods of treatment of hyperproliferative cell disorders
GB0325031D0 (en) * 2003-10-27 2003-12-03 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
WO2010036813A1 (fr) 2010-04-01
US20110243957A1 (en) 2011-10-06

Similar Documents

Publication Publication Date Title
WO2011014255A8 (fr) Traitement de la maladie de crohn au moyen de laquinimod
WO2010036813A8 (fr) Composes et methodes de prevention ou de traitement des affections neurodegeneratives associees a une accumulation de peptides abeta
WO2016210372A3 (fr) Procédés de traitement de maladies neurologiques
NO20074999L (no) Metode og preparat for behandling av perifere vaskulaere sykdommer
WO2008050329A3 (fr) NOUVEAUX ARNsi ET PROCÉDÉS D'UTILISATION DE CEUX-CI
MX2014002459A (es) Inhibidores de quinurenina-3-monooxigenasa, composiciones farmaceuticas y metodos de uso de los mismos.
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
PH12017502049A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2012286851A8 (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2006098603A3 (fr) Composition renfermant de l'isoorientine pour suppression d'histamine
WO2008011083A3 (fr) Composés destinés à renforcer l'activité de l'arginase et procédés d'utilisation
NZ589807A (en) Method for preventing and treating neurodegenerative diseases using a grape seed extract having less than 12% by weight galloylated proanthocyanidins
WO2008016659A3 (fr) Agents pour le traitement des maladies neurodégénératives
WO2009036149A3 (fr) Procédés de traitement d'une maladie dégénérative associée à l'apoptose
WO2008029169A3 (fr) Procédé de traitement de troubles respiratoires
WO2008048410A3 (fr) Procédés diagnostiques et marqueurs génétiques pour la maladie d'alzheimer
WO2008157787A3 (fr) Tolans hydroxylés et composés apparentés dans le traitement du cancer
JP2018502884A5 (fr)
WO2007057508A3 (fr) Traitement de la douleur
TW200742580A (en) Methods for treating nephrolithiasis
WO2007143185A3 (fr) Traitement de tendinopathie active persistante utilisant le trinitrate de glycéryle transdermique présentant un effet durable
WO2006102899A3 (fr) Traitement ou prevention du prurit
WO2012050921A3 (fr) Peptides nd2 et procédés de traitement d'une maladie neurologique
WO2012162211A3 (fr) Oligonucléotides antisens dirigés contre la sphingomyélinase neutre et inhibiteur gw4869 de la sphingomyélinase neutre pour traiter les maladies neurologiques dégénératives
WO2006101910A3 (fr) Composes peptidiques et procedes d'utilisation de composes peptidiques dans le traitement d'etats pathologiques affectant les systemes cardiaque, pulmonaire et nerveux

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09816861

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 13120633

Country of ref document: US

122 Ep: pct application non-entry in european phase

Ref document number: 09816861

Country of ref document: EP

Kind code of ref document: A1